Results 171 to 180 of about 1,093,896 (249)

CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib

British Journal of Haematology, EarlyView.
Summary Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood.
Omar Faruq, Deepak Iyer, Patrick Wang, Mariusz Shrestha, Cuihong Wei, Aaron D. Schimmer, Hong Chang   +6 more
wiley   +1 more source

Japanese evidence on Janus kinase inhibitors for rheumatoid arthritis: a narrative review of risk-optimized use. [PDF]

Front Pharmacol
Matsumoto H, Yoshida S, Tahara M, Nibu H, Yamamoto S, Sakamoto T, Ogawa S, Saito K, Sumichika Y, Suzuki E, Asano T, Sato S, Shimojima Y.   +12 more
europepmc   +1 more source

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source

Janus kinase inhibitors are of limited use in refractory JIA-associated uveitis: retrospective data from a tertiary uveitis center. [PDF]

Pediatr Rheumatol Online J
Baquet-Walscheid K, Wortmann C, Rothaus K, Ohlmeier C, Heinz C, Windschall D, Heiligenhaus A.   +6 more
europepmc   +1 more source

Janus kinase inhibitors in giant cell arteritis: unmet needs and new challenges. [PDF]

Reumatologia
Gkouvi A, Patrikiou E, Grammatikopoulou MG, Bogdanos DP.   +3 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Algorithms in Allergy: Treatment of Hypereosinophilic Syndromes, 2026 Update

Allergy, EarlyView.
Guillaume Lefèvre, Florence Roufosse, Giacomo Emmi, Andreas Reiter, Emmanuel Ledoult, Jean‐Emmanuel Kahn   +5 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis. [PDF]

Clin Pharmacol Ther
Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Maconi G, Gravina AG, Pellegrino R, Bodini G, Savarino EV, Papa A, Italian Network for Inflammatory Bowel Diseases (IN‐IBD).   +11 more
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source